More Than $83,000 Raised Benefiting Boys & Girls Clubs of NEPA, Employment Opportunity and Training Center, and Marley’s Mission
Press Release
SCRANTON, PA, September 18, 2014 /3BL Media/ – Tonight VaxServe, Sanofi Pasteur, and hundreds of community enthusiasts continued their commitment to assisting local children in need at the seventh annual Lackawanna County Community Fundraiser.
The “Jazzin’ It Up” initiative – held at POSH – raised more than $83,000 to benefit the Boys and Girls Clubs of Northeastern Pennsylvania, EOTC (Equal Opportunity Training Center) and Marley’s Mission -- three Lackawanna County organizations that assist children and families at risk through educational, developmental and therapy programs.
July 31, 2014 /3BL Media/ - Earlier this month, at the 11th annual Pocono Mountains Community Fundraiser, Sanofi Pasteur executives revealed more than $2 million has been raised through its ongoing signature fundraising programs. These programs benefit critical Pennsylvania community non-profit organizations.
The recent measles outbreaks in communities around the country serve as a stark reminder that when large groups of people are unvaccinated, it leaves them unprotected and vulnerable to disease outbreaks.
East Stroudsburg, PA, December 20, 2013 – Sanofi Pasteur, the vaccines division of Sanofi, announced today that its employees and contractors collected and hand-delivered a record number of gifts, non-perishable food items, and supermarket gift cards to Pocono Services for Families and Children (PSFC). These contributions will benefit the non-profit organization’s neediest families.
Vaccine Discovery Partnership (VxDP) announcement at the Foundation’s Grand Challenges Meeting in Rio de Janeiro signals commitment to find solutions to the challenges facing the developing world
Press Release
October 30, 2013 /3BL Media/ - GSK and the Bill & Melinda Gates Foundation (BMGF) today announced the launch of a new joint initiative that will endeavour to make vaccines more resistant to heat, thus reducing the need for refrigeration. GSK and BMGF will invest a combined $1.8 million in early stage research into vaccine thermostability.
Most vaccines must be kept cold and transported under constant refrigeration via a so-called ‘cold chain’ which is a significant challenge in hot, remote and resource-limited regions.
JPMorgan Chase, the Bill & Melinda Gates Foundation and partners announce successful capital raise for first-of-its-kind investment product
Press Release
NEW YORK, September 23, 2013 /3BL Media/ - A new investment fund structured by JPMorgan Chase & Co. (NYSE: JPM) and the Bill & Melinda Gates Foundation will, for the first time, allow individual and institutional investors the opportunity to finance late-stage global health technologies that have the potential to save millions of lives in low-income countries.
Last night, GSK was honoured by The Pharmaceutical Research and Manufacturers of America (PhRMA) with the "The Research and Hope Award" which highlights individuals or a team from a biopharmaceutical company for outstanding research in the area ofvaccines.
Collaborative study utilizing Vaccine Safety Datalink published in the American Journal of Preventive Medicine
Press Release
San Diego, CA, June 11, 2013 /3BL Media/ – In a study using the Vaccine Safety Datalink (VSD), investigators analyzed four years of data and determined that background mortality rates (rates of death irrespective of cause) are crucial in interpreting the numbers of deaths following vaccination. The VSD mortality rate following immunization is lower than the general US population mortality rate, and the causes of death are similar. These background rates can be used in communications to the public about vaccine safety risks, reports the American Journal of Preventive Medicine.
May 10, 2013 /3BL Media/ - GlaxoSmithKline (GSK) today announced a new commitment to the GAVI Alliance to supply its cervical cancer vaccine as part of a new long term programme to help protect girls against cervical cancer in the world’s poorest countries. To start the programme and over the next two years, GSK will supply doses of Cervarix® (Human Papillomavirus vaccine [Types 16, 18] (Recombinant, adjuvanted, adsorbed)) to four new GAVI demonstration projects at a significantly discounted price of $4.60 per dose.
